ITG's primary portfolio is the Biolab range — antimicrobial matrices, amniotic tissue allografts, bioengineered wound products, and cold plasma therapy, with full clinical documentation in English and Thai. ITG also has access to the SurGraft® family of dehydrated human amniotic membrane allografts for markets where that product line is indicated. Every product across both portfolios is shelf-stable, supported by peer-reviewed evidence, and backed by ITG's regulatory and clinical infrastructure.
ITG's primary distribution focus is the Biolab range of advanced wound care products across Asia — antimicrobial matrices, amniotic tissue allografts, bioengineered wound products, and cold plasma therapy. Full clinical documentation available in English and Thai.
Ionic and metallic silver at low, non-toxic levels — 99.99% reduction of a broad range of microbes on the matrix. Conforms to wound-bed micro-crevices, maintains a moist healing environment. Available in 7 sizes (16mm disc through 10×10 cm). HCPCS A2005.
Microlyte® combined with a unit-dose of lidocaine HCl — simultaneous infection control and pain relief. Releases >80% lidocaine within 30 minutes. FDA 510(k) cleared (K211943). Available in 3×3, 5×5, 10×10 cm. HCPCS A2040.
Four amniotic tissue allograft configurations: Membrane Wrap™ (dual-layer), Membrane Wrap - Hydro™ (hydrated dual-layer), Membrane Wrap - Lite™ (single-layer), and Tri-Membrane Wrap™ (triple-layer amnion-chorion-amnion). All available in sizes 1×1 through 10×10 cm. 5-year shelf life, FDA compliant.
Collagen Derivative + Mānuka Honey + Hydroxyapatite — published in multiple peer-reviewed studies demonstrating 2× faster wound closure. 4–8 week wound closure, 99.99% bacteria reduction in 24 hours. Three sizes. Established HCPCS code A2010.
In addition to its Biolab portfolio, ITG has access to SurGraft® dehydrated human amniotic membrane allografts derived from full-term healthy Caesarean sections, processed and sterilized via proprietary Surgenex methods. Rich in growth factors, anti-inflammatory proteins, and extracellular matrix components — available for chronic wound and complex surgical applications where indicated.
The foundational amniotic membrane allograft — proven in chronic wound care, surgical applications, and complex tissue defects.
Extended-thickness construct providing enhanced scaffold support for more challenging wound environments.
Triple-layer configuration for the most complex wounds — sufficient substance to be sutured, compatible with negative-pressure wound vacs.
Dehydrated amniotic membrane allograft purpose-formulated for corneal repair, reconstruction, and ophthalmic surgical applications.
Average wound area reduction at 8 weeks across 10 patients with chronic non-healing foot ulcers (Wagner Grade 1 & 2). 99.4% reduction in non-diabetic patients, 81.4% in diabetic patients.
Wound area reduction observed within just one week of initial SurGraft® application. Median of 3.5 graft applications. Zero adverse reactions reported across the study.
The amniotic membrane allografts ITG distributes are not emerging research. They are clinically-validated, regulatory-cleared, and supported by peer-reviewed evidence across chronic, surgical, and ophthalmic applications.
Our team can provide product specifications, peer-reviewed citations, regulatory documentation, and country-specific availability for any of the platforms above.
Request Product Information